Clinical Trial Update: Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors [Phase 2]

View source ↗

Summary

Phase II study of ilorasertib (ABT-348) in CDKN2A-deficient solid tumors was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solitary Solid Tumors

Drugs mentioned

• Ilorasertib (ABT-348) (ilorasertib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Cancers | Phase 2 | Status: TERMINATED | Results posted: 2023-07-17